The aim of the present study was to determine whether treatment with
polymyxin B-immobilized fibre (PMX-F) haemoperfusion,
teicoplanin, or both in combination is effective in patients with methicillin-resistant Staphylococcus aureus (MRSA)
sepsis. Sixty patients with MRSA
sepsis were randomly assigned to one of four treatments: (A) PMX-F treatment (N=15), (B)
teicoplanin treatment (N=15), (C) PMX-F and
teicoplanin in combination (N=20) and (D) conventional
therapy (N=10). PMX-F treatment was repeated twice.
Teicoplanin was administered by
intravenous injection. Plasma
endotoxin levels were determined by endospecy test. Plasma
endotoxin levels were reduced in groups A and C (P<0.05). Survival rates were 53, 47, 90, and 20% in groups A, B, C and D, respectively (group C versus group A, P<0.05; group C versus group B, P<0.01; group C versus group D,P <0.001). The mean duration of stay was 44, 42, 28 and 56 days in groups A, B, C and D, respectively. Our data suggest that combination
therapy with PMX-F and
teicoplanin is effective for
sepsis caused by MRSA.